In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development

Figure 6

Detection of nonspecific background signals in drug- and D-PBS-treated serum samples. (a–b) Detection of a nonspecific binding response from 1 mg/kg Quad-X™- and Humira®-treated mouse serum samples, respectively. In a direct-binding ELISA, 2 μg/mL human serum albumin (HSA) was used as coating antigen and nonspecific binding was measured using an anti-mouse IgG- (whole molecule) peroxidase antibody. The results shown are the ( with three replicates per experiment, except for the pooled NDure™ Std data which is an with two replicates per experiment). for all Quad-X- and Humira-treated serum samples vs. D-PBS-treated serum samples, for NDure™-treated vs. D-PBS-treated serum samples. Results were analysed statistically using a two-way ANOVA with multiple comparison post hoc test ( is considered not significant).

(a)

(b)